2 In our clinical experience, approximately 20% of patients with moderate-to-severe psoriasis are currently treated with anti-TNF agents including etanercept, infliximab and adalimumab.

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

with both etanercept and adalimumab. Usually managed with steroids and antihistamine, occasionally requiring a change of anti-TNF agent. Infliximab is associated with infusion reactions ...

with both etanercept and adalimumab. Usually managed with steroids and antihistamine, occasionally requiring a change of anti-TNF agent. Infliximab is associated with infusion reactions ...

Of these, just over half were on anti-TNF agents while therapy ... drugs for at least 6 months. TNF inhibitors used in these patients included etanercept (Enbrel), infliximab (Remicade ...

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...